← Research library

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2

Patent disclosure · 2017

What the patent describes
Patent chemistry and preclinical examples
Reported evidence
The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.

BDNF-model behavior · GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it · Different molecules; the unfavorable direction is retained

Reported patent results

Findings described in words

Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.

Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.

Population or model Patent chemistry and preclinical examples

Results · Selected neuronal-viability examples and final Porsolt comparisons, Figures 2.12–2.13.
MeasureResultComparison, timing and statistics
BDNF-model behaviorGSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
Candidate identity and viabilitySome monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
Reporting conflictGSB-104 descriptions and GK-2f structure mapping require reconciliationNo single pooled efficacy percentage inferred from inconsistent examples

The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Platform context. The title refers to NGF and BDNF mimetics, but the granted US claims specifically identify a Ser-Lys-based dimer. This is not a grant to every GK, GSB, GBK or GTS candidate.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US9683014B2 ↗ · 2017-06-20
Earliest priority / filing
2009-02-16 / 2014-08-15
Original applicant / assignee
Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-Issledovatelsky Institut Farmakologii Imeni Vvzakusova Ramn
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
42561958 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dipeptide mimetics of NGF and BDNF neurotrophins

Inventors: Sergey Borisovich Seredenin; Alexandrovna Tatyana GUDASHEVA.

US9683014B2 · US20110312895A1 · EP2397488B1 · CN102365294B · RU2410392C2 · WO2010093284A1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent proposals are not established clinical uses.
  • Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.

Source details

Selected original-source text checked; full methodological review pending.

Selected text reviewed

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 Primary source linked above

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards